JP7050759B2 - 縮合二環式ｓｇｃ刺激剤 - Google Patents

縮合二環式ｓｇｃ刺激剤 Download PDF

Info

Publication number
JP7050759B2
JP7050759B2 JP2019512205A JP2019512205A JP7050759B2 JP 7050759 B2 JP7050759 B2 JP 7050759B2 JP 2019512205 A JP2019512205 A JP 2019512205A JP 2019512205 A JP2019512205 A JP 2019512205A JP 7050759 B2 JP7050759 B2 JP 7050759B2
Authority
JP
Japan
Prior art keywords
disease
disorder
independently
pulmonary
dementia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019512205A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019526582A (ja
JP2019526582A5 (enExample
Inventor
レニー，グレン・ロバート
アイアンガー，ラジェシュ・アール
リー，トーマス・ワイ－ホー
タカシ ナカイ
マーメリアン，アラ
ジア，レイ
イム，ギュン・ジェイミー
レンハウ，ポール・アラン
ユング，ジュン
ジェルマーノ，ピーター
イヤー，カルティク
バーデン，ティモシー・クロード
タン，キム
Original Assignee
サイクレリオン・セラピューティクス，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サイクレリオン・セラピューティクス，インコーポレーテッド filed Critical サイクレリオン・セラピューティクス，インコーポレーテッド
Publication of JP2019526582A publication Critical patent/JP2019526582A/ja
Publication of JP2019526582A5 publication Critical patent/JP2019526582A5/ja
Priority to JP2022050708A priority Critical patent/JP7628096B2/ja
Application granted granted Critical
Publication of JP7050759B2 publication Critical patent/JP7050759B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
JP2019512205A 2016-09-02 2017-09-01 縮合二環式ｓｇｃ刺激剤 Active JP7050759B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022050708A JP7628096B2 (ja) 2016-09-02 2022-03-25 縮合二環式ｓｇｃ刺激剤

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201662382942P 2016-09-02 2016-09-02
US62/382,942 2016-09-02
US201662423445P 2016-11-17 2016-11-17
US62/423,445 2016-11-17
US201762468598P 2017-03-08 2017-03-08
US62/468,598 2017-03-08
US201762482486P 2017-04-06 2017-04-06
US62/482,486 2017-04-06
PCT/US2017/049834 WO2018045276A1 (en) 2016-09-02 2017-09-01 Fused bicyclic sgc stimulators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022050708A Division JP7628096B2 (ja) 2016-09-02 2022-03-25 縮合二環式ｓｇｃ刺激剤

Publications (3)

Publication Number Publication Date
JP2019526582A JP2019526582A (ja) 2019-09-19
JP2019526582A5 JP2019526582A5 (enExample) 2020-10-15
JP7050759B2 true JP7050759B2 (ja) 2022-04-08

Family

ID=59887396

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019512205A Active JP7050759B2 (ja) 2016-09-02 2017-09-01 縮合二環式ｓｇｃ刺激剤
JP2022050708A Active JP7628096B2 (ja) 2016-09-02 2022-03-25 縮合二環式ｓｇｃ刺激剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022050708A Active JP7628096B2 (ja) 2016-09-02 2022-03-25 縮合二環式ｓｇｃ刺激剤

Country Status (30)

Country Link
US (5) US10472363B2 (enExample)
EP (2) EP3507291B1 (enExample)
JP (2) JP7050759B2 (enExample)
KR (2) KR102854313B1 (enExample)
CN (2) CN109790167B (enExample)
AU (2) AU2017321810B2 (enExample)
CA (1) CA3035210A1 (enExample)
CL (1) CL2019000486A1 (enExample)
CO (1) CO2019001760A2 (enExample)
CR (2) CR20190101A (enExample)
CY (1) CY1124612T1 (enExample)
DK (1) DK3507291T3 (enExample)
ES (2) ES2885003T3 (enExample)
HR (1) HRP20211355T1 (enExample)
HU (1) HUE056051T2 (enExample)
IL (2) IL292968B2 (enExample)
LT (1) LT3507291T (enExample)
MA (1) MA53999A (enExample)
MX (3) MX383782B (enExample)
MY (1) MY199759A (enExample)
NZ (2) NZ750849A (enExample)
PE (1) PE20190607A1 (enExample)
PH (1) PH12019500461B1 (enExample)
PL (1) PL3507291T3 (enExample)
PT (1) PT3507291T (enExample)
RS (1) RS62256B1 (enExample)
SG (1) SG11201901729YA (enExample)
SI (1) SI3507291T1 (enExample)
TW (2) TWI750218B (enExample)
WO (1) WO2018045276A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033217A1 (fr) * 1997-01-24 1998-07-30 Rohm Co., Ltd. Dispositif a semi-conducteur et procede pour produire ce dispositif
JP2021515015A (ja) * 2018-03-07 2021-06-17 サイクレリオン・セラピューティクス，インコーポレーテッド Ｓｇｃ刺激因子の結晶形態
JP2022084863A (ja) * 2016-09-02 2022-06-07 サイクレリオン・セラピューティクス，インコーポレーテッド 縮合二環式ｓｇｃ刺激剤

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3194386A2 (en) * 2014-09-17 2017-07-26 Ironwood Pharmaceuticals, Inc. Sgc stimulators
CA3015172A1 (en) 2016-02-18 2017-08-24 Privo Technologies, Inc. Two-stage microparticle-based therapeutic delivery system and method
CN110267658B (zh) * 2016-11-08 2024-02-02 帝善多制药公司 用sGC刺激剂治疗CNS疾病
WO2018151849A1 (en) 2017-02-17 2018-08-23 Privo Technologies, Inc. Particle-based multi-layer therapeutic delivery device and method
US10478403B1 (en) 2017-05-03 2019-11-19 Privo Technologies, Inc. Intraoperative topically-applied non-implantable rapid release patch
BR122023024273A2 (pt) 2018-02-27 2024-02-20 Incyte Corporation Compostos imidazopirimidinas e triazolopirimidinas, seus usos, método para inibir uma atividade de um receptor de adenosina e composição farmacêutica dos mesmos
CA3092680A1 (en) * 2018-03-07 2019-09-12 Cyclerion Therapeutics, Inc. Process for preparing soluble guanylate cyclase stimulators
EP3787610A1 (en) * 2018-04-30 2021-03-10 Bayer Aktiengesellschaft The use of sgc activators and sgc stimulators for the treatment of cognitive impairment
WO2019222677A1 (en) 2018-05-18 2019-11-21 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
JOP20200342A1 (ar) 2018-07-05 2020-12-30 Incyte Corp مشتقات بيرازين مدمجة كمثبطات a2a/a2b
KR20210031931A (ko) 2018-07-11 2021-03-23 사이클리온 테라퓨틱스, 인크. 미토콘드리아 장애의 치료를 위한 sGC 자극제의 용도
GB201811695D0 (en) * 2018-07-17 2018-08-29 Salvensis Compounds for use in the treatment of fascioliasis
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
KR20210096626A (ko) * 2018-11-28 2021-08-05 토파두르 파마 아게 가용성 구아닐레이트 사이클라제 활성제 및 포스포디에스테라제 억제제의 신규한 이중 작용 방식 및 이의 용도
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
CN110305125B (zh) * 2019-06-06 2021-09-03 山东新华制药股份有限公司 5-嘧啶-6-氧-吡唑并吡啶类衍生物及其制备方法和应用
CA3162893A1 (en) * 2019-11-26 2021-06-03 Praxis Precision Medicines, Inc. Ion channel modulators
US20230130739A1 (en) 2020-03-26 2023-04-27 Cyclerion Therapeutics, Inc. DEUTERATED sGC STIMULATORS
TW202228697A (zh) 2020-10-13 2022-08-01 美商賽克瑞恩醫療公司 以CNS穿透性sGC刺激劑治療認知損傷
CR20230532A (es) 2021-04-20 2024-03-22 Tisento Therapeutics Inc ESTIMULADORES DE GUANILIL CICLASA SOLUBLE (sGC)
EP4326268A1 (en) 2021-04-20 2024-02-28 Tisento Therapeutics Inc. Treatment of cns diseases with sgc stimulators
US20240099979A1 (en) * 2021-06-01 2024-03-28 Privo Technologies, Inc. Enhanced two-stage microparticle-based localized therapeutic delivery system
EP4472620A1 (en) 2022-02-01 2024-12-11 Charité - Universitätsmedizin Berlin A soluble guanylat cyclase activator for treating chronic vascular dysfunction
US20230277521A1 (en) * 2022-03-07 2023-09-07 Harrow Ip, Llc Extended-release pharmaceutical compositions for treating eye conditions
CN120112293A (zh) 2022-10-18 2025-06-06 帝善多制药公司 使用sGC刺激剂治疗线粒体疾病
CN119285629A (zh) * 2024-09-03 2025-01-10 中南大学 5-[1,2,4-噁二唑]-6-氧-吡唑并吡啶类衍生物及其制备方法和应用
CN119185590B (zh) * 2024-11-28 2025-02-25 华润双鹤利民药业（济南）有限公司 羟丙基-β-环糊精在制备维立西呱固体制剂中的应用、固体制剂及制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015187470A1 (en) 2014-06-04 2015-12-10 Merck Sharp & Dohme Corp. Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators
WO2016044446A2 (en) 2014-09-17 2016-03-24 Ironwood Pharmaceuticals, Inc. Sgc stimulators
WO2016081668A1 (en) 2014-11-21 2016-05-26 Merck Sharp & Dohme Corp. Triazolo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
WO2016087342A1 (de) 2014-12-02 2016-06-09 Bayer Pharma Aktiengesellschaft Substituierte pyrazolo[1,5-a]pyridine und imidazo[1,2-a]pyrazine und ihre verwendung

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3995631A (en) 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US4203440A (en) 1978-10-23 1980-05-20 Alza Corporation Device having variable volume chamber for dispensing useful agent
US4627850A (en) 1983-11-02 1986-12-09 Alza Corporation Osmotic capsule
EP0192963B1 (de) 1985-02-27 1988-07-20 Werkzeugmaschinenfabrik Oerlikon-Bührle AG Schwingungsmesseinrichtung für ein Spiralkegelradgetriebe auf einer Zahnradprüfmaschine
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5324280A (en) 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
JP2928079B2 (ja) 1994-02-14 1999-07-28 永信薬品工業股▲ふん▼有限公司 １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
DE19744026A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
EP1614678B1 (en) 1998-07-08 2014-01-01 Sanofi-Aventis Deutschland GmbH Sulfur substituted sulfonylaminocarboxylic acid N-heteroarylamides, their preparation, their use and pharmaceutical preparations comprising them
DE19830430A1 (de) 1998-07-08 2000-01-13 Hoechst Marion Roussel De Gmbh Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
GB9824310D0 (en) 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
CN1161101C (zh) 1998-12-17 2004-08-11 阿尔扎有限公司 用多层包衣将填充液体的明胶胶囊转变成控制释放的系统
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
DE19942809A1 (de) 1999-09-08 2001-03-15 Bayer Ag Verfahren zur Herstellung substituierter Pyrimidinderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
US6720317B1 (en) 1999-09-17 2004-04-13 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US6844367B1 (en) 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
EP1259485B1 (en) 2000-02-29 2005-11-30 Millennium Pharmaceuticals, Inc. BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa
WO2003059346A1 (en) 2002-01-18 2003-07-24 The Genetics Company Inc. Beta-secretase inhibitors
DE10216145A1 (de) 2002-04-12 2003-10-23 Bayer Ag Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
KR20060033033A (ko) 2003-08-04 2006-04-18 화이자 프로덕츠 인크. 콜레스테릴 에스테르 전달 단백질 억제제의 제어 방출 및ｈｍｇ-ｃｏａ 리덕타제 억제제의 순간 방출을 제공하는제형
AU2004268621C1 (en) 2003-08-29 2011-08-18 Exelixis, Inc. c-Kit modulators and methods of use
DE102006020327A1 (de) 2006-04-27 2007-12-27 Bayer Healthcare Ag Heterocyclisch substituierte, anellierte Pyrazol-Derivate und ihre Verwendung
MX2010002608A (es) 2007-09-06 2010-06-01 Merck Sharp & Dohme Activadores de guanilato ciclasas solubles.
EP2244575B1 (en) 2008-01-24 2013-07-17 Merck Sharp & Dohme Corp. Angiotensin ii receptor antagonists
AU2009322836B2 (en) 2008-11-25 2013-04-04 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
GB0822981D0 (en) 2008-12-17 2009-01-21 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
WO2010088518A2 (en) 2009-01-31 2010-08-05 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
CN102414194A (zh) 2009-02-26 2012-04-11 默沙东公司 可溶性鸟苷酸环化酶激活剂
EP2480546B1 (en) 2009-09-24 2014-12-31 F. Hoffmann-La Roche AG Imidazopyridine or imidazopyrimidine derivatives as phosphodiesterase 10A inhibitors
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
US9284301B2 (en) 2010-03-25 2016-03-15 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
KR20140019004A (ko) 2010-05-27 2014-02-13 머크 샤프 앤드 돔 코포레이션 가용성 구아닐레이트 시클라제 활성화제
EP3173407A1 (en) 2010-06-30 2017-05-31 Ironwood Pharmaceuticals, Inc. Sgc stimulators
WO2012058132A1 (en) 2010-10-28 2012-05-03 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
NZ609955A (en) * 2010-11-09 2015-05-29 Ironwood Pharmaceuticals Inc Sgc stimulators
JP5937102B2 (ja) 2010-12-14 2016-06-22 エレクトロフォレティクス リミテッド カゼインキナーゼ１デルタ（ｃｋ１デルタ）阻害剤
CN104066731B (zh) * 2011-12-27 2016-06-15 铁木医药有限公司 可用作sgc刺激剂的2-苄基、3-(嘧啶-2-基)取代的吡唑类
DE102012200349A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung
US9309235B2 (en) * 2012-09-18 2016-04-12 Ironwood Pharmaceuticals, Inc. SGC stimulators
US9624214B2 (en) 2012-11-05 2017-04-18 Bayer Pharma Aktiengesellschaft Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
CA2907111C (en) * 2013-03-15 2023-10-24 Joel Moore Sgc stimulators
CA2933250A1 (en) 2013-12-11 2015-06-18 Ironwood Pharmaceuticals, Inc. Sgc stimulators
EP3303342B1 (en) 2015-05-27 2021-03-17 Merck Sharp & Dohme Corp. Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
US10213429B2 (en) 2015-05-28 2019-02-26 Merck Sharp & Dohme Corp. Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
WO2017002120A1 (en) 2015-07-02 2017-01-05 Yeda Research And Development Co. Ltd. Selective inhibitors of senescent cells and uses thereof
WO2017108441A1 (en) 2015-12-22 2017-06-29 Universiteit Maastricht Treatment of cognitive impairment with cgc stimulator
DK3397631T3 (da) 2015-12-29 2021-05-25 Pfizer Substituerede 3-azabicyclo[3.1.0]hexaner som ketohexokinase-inhibitorer
US10472363B2 (en) 2016-09-02 2019-11-12 Cyclerion Therapeutics, Inc. SGC stimulators
GB201614934D0 (en) 2016-09-02 2016-10-19 Glaxosmithkline Intellectual Property (No 2) Ltd Chemical compounds
TWI886480B (zh) 2017-04-06 2025-06-11 美商富曼西公司 殺真菌之噁二唑
KR102698575B1 (ko) 2017-04-06 2024-08-26 항저우 디에이씨 바이오테크 씨오, 엘티디 비스-링키지를 사용한 세포독성 약물의 접합

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015187470A1 (en) 2014-06-04 2015-12-10 Merck Sharp & Dohme Corp. Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators
WO2016044446A2 (en) 2014-09-17 2016-03-24 Ironwood Pharmaceuticals, Inc. Sgc stimulators
WO2016081668A1 (en) 2014-11-21 2016-05-26 Merck Sharp & Dohme Corp. Triazolo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
WO2016087342A1 (de) 2014-12-02 2016-06-09 Bayer Pharma Aktiengesellschaft Substituierte pyrazolo[1,5-a]pyridine und imidazo[1,2-a]pyrazine und ihre verwendung

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033217A1 (fr) * 1997-01-24 1998-07-30 Rohm Co., Ltd. Dispositif a semi-conducteur et procede pour produire ce dispositif
JP2022084863A (ja) * 2016-09-02 2022-06-07 サイクレリオン・セラピューティクス，インコーポレーテッド 縮合二環式ｓｇｃ刺激剤
JP7628096B2 (ja) 2016-09-02 2025-02-07 ティセント セラピューティクス インコーポレーテッド 縮合二環式ｓｇｃ刺激剤
JP2021515015A (ja) * 2018-03-07 2021-06-17 サイクレリオン・セラピューティクス，インコーポレーテッド Ｓｇｃ刺激因子の結晶形態
JP7423539B2 (ja) 2018-03-07 2024-01-29 ティセント セラピューティクス インコーポレーテッド Ｓｇｃ刺激因子の結晶形態
US12122782B2 (en) 2018-03-07 2024-10-22 Tisento Therapeutics Inc. Crystalline forms of 8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine as sGC stimulators

Also Published As

Publication number Publication date
CN117105939A (zh) 2023-11-24
CY1124612T1 (el) 2022-07-22
KR102854313B1 (ko) 2025-09-04
IL292968A (en) 2022-07-01
MX2019002313A (es) 2019-07-08
US10858363B2 (en) 2020-12-08
WO2018045276A8 (en) 2018-04-26
US20180065971A1 (en) 2018-03-08
DK3507291T3 (da) 2021-08-30
MX2021007580A (es) 2022-08-23
AU2017321810A1 (en) 2019-03-07
JP7628096B2 (ja) 2025-02-07
IL292968B2 (en) 2025-10-01
AU2022202167A1 (en) 2022-04-21
AU2017321810B2 (en) 2022-01-27
US20250326761A1 (en) 2025-10-23
EP3872080C0 (en) 2023-08-16
IL292968B1 (en) 2025-06-01
EP3507291B1 (en) 2021-05-26
US20190248794A1 (en) 2019-08-15
TW202229284A (zh) 2022-08-01
NZ791931A (en) 2025-09-26
CA3035210A1 (en) 2018-03-08
CN109790167B (zh) 2023-06-20
TWI813078B (zh) 2023-08-21
LT3507291T (lt) 2021-09-10
TWI750218B (zh) 2021-12-21
CR20190101A (es) 2019-07-04
BR112019004468A2 (pt) 2019-05-28
NZ750849A (en) 2025-09-26
AU2022202167B2 (en) 2024-03-14
EP3507291A1 (en) 2019-07-10
PH12019500461B1 (en) 2023-08-09
CL2019000486A1 (es) 2019-06-07
PT3507291T (pt) 2021-08-30
HUE056051T2 (hu) 2022-01-28
KR20230124760A (ko) 2023-08-25
MY199759A (en) 2023-11-21
US10472363B2 (en) 2019-11-12
US11731977B2 (en) 2023-08-22
MA53999A (fr) 2022-04-06
RS62256B1 (sr) 2021-09-30
EP3872080A1 (en) 2021-09-01
WO2018045276A1 (en) 2018-03-08
MX394958B (es) 2025-03-24
KR102568384B1 (ko) 2023-08-22
SI3507291T1 (sl) 2021-11-30
ES2957159T3 (es) 2024-01-12
MX383782B (es) 2025-03-14
PL3507291T3 (pl) 2021-11-22
CO2019001760A2 (es) 2019-05-31
IL264955B (en) 2022-06-01
PH12019500461A1 (en) 2019-06-03
ES2885003T3 (es) 2021-12-13
PE20190607A1 (es) 2019-04-23
US20220009937A1 (en) 2022-01-13
US20210087198A1 (en) 2021-03-25
HRP20211355T1 (hr) 2021-11-26
JP2019526582A (ja) 2019-09-19
EP3872080B1 (en) 2023-08-16
JP2022084863A (ja) 2022-06-07
MX2021007579A (es) 2021-08-11
SG11201901729YA (en) 2019-03-28
TW201811798A (zh) 2018-04-01
CR20220309A (es) 2022-09-16
CN109790167A (zh) 2019-05-21
KR20190043158A (ko) 2019-04-25

Similar Documents

Publication Publication Date Title
JP7050759B2 (ja) 縮合二環式ｓｇｃ刺激剤
EP3538520B1 (en) CGS STIMULATORS
JP7150740B2 (ja) ｓＧＣ刺激薬による中枢神経系疾患の治療
HK40061428B (en) Fused bicyclic sgc stimulators
HK40061428A (en) Fused bicyclic sgc stimulators
HK40010650B (en) Fused bicyclic sgc stimulators
HK40010650A (en) Fused bicyclic sgc stimulators
BR112019004468B1 (pt) Estimulantes de sgc

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20190710

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190710

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200901

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200901

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210708

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210804

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211104

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220304

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220329

R150 Certificate of patent or registration of utility model

Ref document number: 7050759

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250